PMID- 34708838
OWN - NLM
STAT- MEDLINE
DCOM- 20211207
LR  - 20211214
IS  - 0300-0729 (Print)
IS  - 0300-0729 (Linking)
VI  - 59
IP  - 6
DP  - 2021 Dec 1
TI  - Multi-institutional minimal clinically important difference of the 22-item 
      Sinonasal Outcome Test in medically managed chronic rhinosinusitis.
PG  - 552-559
LID - 10.4193/Rhin21.253 [doi]
AB  - BACKGROUND: With a rapid proliferation of clinical trials to study novel medical 
      treatments for CRS, the objective of this study was to study the minimal 
      clinically important difference (MCID) of the 22-item Sinonasal Outcome Test 
      (SNOT-22) in medically-managed CRS patients. METHODS: A total of 183 
      medically-treated CRS patients were recruited. All patients completed a SNOT-22 
      at enrollment and subsequent follow up visit. Distribution and anchor-based 
      methods were used for MCID calculation. These data were combined with data from a 
      previously published study on SNOT-22 MCID in 247 medically managed CRS patients 
      to determine a final recommended MCID value using the combined cohort of 430 
      patients. RESULTS: In our cohort, distribution- and anchor-based methods -"using 
      both sinus-specific and general health anchors-"provided greatest support for a 
      12-point SNOT-22 MCID, which had approximately 55% sensitivity but 81% 
      specificity for detecting patients explicitly reporting improvement in their 
      sinus symptoms and general health. In the combined cohort of 430 patients, we 
      also found greatest support for a 12-point SNOT-22 MCID, which had approximately 
      57% sensitivity and 81% specificity for detecting patients explicitly reporting 
      improvement in their sinus symptoms and general health. We also find evidence 
      that the MCID value may be higher in CRS patients without nasal polyps compared 
      to those with nasal polyps. CONCLUSIONS: Our results - which include data from 
      patients from two different institutions and regions - confirm a SNOT-22 MCID of 
      12 in medically managed CRS patients. The SNOT-22 MCID was specific but not 
      sensitive for identifying CRS patients experiencing improvement in symptoms or 
      general health.
FAU - Phillips, K M
AU  - Phillips KM
AD  - Department of Otolaryngology - Head and Neck Surgery, University of Cincinnati 
      College of Medicine, Cincinnati, OH, USA.
FAU - Houssein, F A
AU  - Houssein FA
AD  - Department of Otolaryngology - Head and Neck Surgery, University of Cincinnati 
      College of Medicine, Cincinnati, OH, USA.
FAU - Boeckermann, L M
AU  - Boeckermann LM
AD  - Department of Otolaryngology - Head and Neck Surgery, University of Cincinnati 
      College of Medicine, Cincinnati, OH, USA.
FAU - Singerman, K W
AU  - Singerman KW
AD  - Department of Otolaryngology - Head and Neck Surgery, University of Cincinnati 
      College of Medicine, Cincinnati, OH, USA.
FAU - Liu, D T
AU  - Liu DT
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of 
      Vienna, Vienna, Austria.
FAU - Sedaghat, A R
AU  - Sedaghat AR
AD  - Department of Otolaryngology - Head and Neck Surgery, University of Cincinnati 
      College of Medicine, Cincinnati, OH, USA.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Rhinology
JT  - Rhinology
JID - 0347242
SB  - IM
MH  - Chronic Disease
MH  - Humans
MH  - Minimal Clinically Important Difference
MH  - *Paranasal Sinuses
MH  - Quality of Life
MH  - *Rhinitis/drug therapy
MH  - Sino-Nasal Outcome Test
MH  - *Sinusitis/drug therapy
EDAT- 2021/10/29 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/10/28 08:41
PHST- 2021/10/29 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/10/28 08:41 [entrez]
AID - 2936 [pii]
AID - 10.4193/Rhin21.253 [doi]
PST - ppublish
SO  - Rhinology. 2021 Dec 1;59(6):552-559. doi: 10.4193/Rhin21.253.